Hepatocellular Carcinoma: Advances and Challenges in Research and Treatment

Dear Colleagues,

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. Although the etiology of viral-hepatitis-related HCC has decreased due to the deployment of aggressive medication and/or vaccines, the etiologies of alcoholic- or nonalcoholic-fatty-liver-disease-related HCC are increasing. The importance of the clinical prevention and management of HCC still cannot be overstated. The new version of the BCLC guidelines recommends corresponding treatment strategies and clinical-outcome estimations for different stages of the disease. However, there still remain other unrecommended treatment modalities which may be beneficial, especially for the advanced HCC patients.

This Special Issue will reflect the recent advances in the research and treatment of HCC, including surgical resection, liver transplant, image-guided tumor ablation, conventional/drug-eluting chemoembolization, Y-90 radioembolization, new regimens of hepatic arterial infusion chemotherapy, proton beam radiotherapy, target/immunotherapy, and/or combination therapy.

Dr. Huei-Lung Liang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.